BEYOND AIR INC (XAIR) Stock Price, Quote, News and Overview
NASDAQ:XAIR - Nasdaq - US08862L1035 - Common Stock - Currency: USD
XAIR Quote, Performance and Key Statistics
0.2
-0.02 (-8.13%)
The current stock price of XAIR is 0.2 USD. In the past month the price decreased by -25.4%. In the past year, price decreased by -84.38%.
XAIR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.1 | 224.65B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.28 | 184.15B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.84 | 151.13B | ||
| SYK | STRYKER CORP | 30.06 | 139.89B | ||
| MDT | MEDTRONIC PLC | 15.74 | 107.78B | ||
| BDX | BECTON DICKINSON AND CO | 14.71 | 58.76B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.05 | 44.41B | ||
| IDXX | IDEXX LABORATORIES INC | 38.58 | 35.17B | ||
| RMD | RESMED INC | 25.79 | 34.39B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.16 | 31.17B | ||
| DXCM | DEXCOM INC | 43.14 | 27.91B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.09 | 23.74B |
Related stock screener links
About XAIR
Company Profile
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 107 full-time employees. The company went IPO on 2019-05-07. The firm has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.
Company Info
BEYOND AIR INC
900 Stewart Avenue, Suite 301
Garden City NEW YORK 11530 US
CEO: Steven Lisi
Employees: 107
Company Website: https://www.beyondair.net/
Investor Relations: http://www.beyondair.net/investors
Phone: 15166658200
BEYOND AIR INC / XAIR FAQ
What is the stock price of BEYOND AIR INC today?
The current stock price of XAIR is 0.2 USD. The price decreased by -8.13% in the last trading session.
What is the ticker symbol for BEYOND AIR INC stock?
The exchange symbol of BEYOND AIR INC is XAIR and it is listed on the Nasdaq exchange.
On which exchange is XAIR stock listed?
XAIR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BEYOND AIR INC stock?
11 analysts have analysed XAIR and the average price target is 2.3 USD. This implies a price increase of 1047.5% is expected in the next year compared to the current price of 0.2. Check the BEYOND AIR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BEYOND AIR INC worth?
BEYOND AIR INC (XAIR) has a market capitalization of 17.66M USD. This makes XAIR a Nano Cap stock.
How many employees does BEYOND AIR INC have?
BEYOND AIR INC (XAIR) currently has 107 employees.
What are the support and resistance levels for BEYOND AIR INC (XAIR) stock?
BEYOND AIR INC (XAIR) has a resistance level at 0.21. Check the full technical report for a detailed analysis of XAIR support and resistance levels.
Is BEYOND AIR INC (XAIR) expected to grow?
The Revenue of BEYOND AIR INC (XAIR) is expected to grow by 172.26% in the next year. Check the estimates tab for more information on the XAIR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEYOND AIR INC (XAIR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XAIR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XAIR, evaluating the profitability, health, valuation and growth aspects
- BEYOND AIR INC (XAIR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEYOND AIR INC (XAIR) Sales and EPS estimates to see what analysts future expectations are.
- BEYOND AIR INC (XAIR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEYOND AIR INC (XAIR) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEYOND AIR INC (XAIR) Stock Chart to make your own analysis
- BEYOND AIR INC (XAIR) Latest news and press-releases to stay up to date.
Does BEYOND AIR INC (XAIR) stock pay dividends?
XAIR does not pay a dividend.
When does BEYOND AIR INC (XAIR) report earnings?
BEYOND AIR INC (XAIR) will report earnings on 2025-06-23, after the market close.
What is the Price/Earnings (PE) ratio of BEYOND AIR INC (XAIR)?
BEYOND AIR INC (XAIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
What is the Short Interest ratio of BEYOND AIR INC (XAIR) stock?
The outstanding short interest for BEYOND AIR INC (XAIR) is 1.91% of its float. Check the ownership tab for more information on the XAIR short interest.
XAIR Technical Analysis
XAIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XAIR. XAIR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XAIR Financial Highlights
Over the last trailing twelve months XAIR reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 50.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -153.17% | ||
| ROE | -296.42% | ||
| Debt/Equity | 0 |
XAIR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to XAIR. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 58.42% and a revenue growth 172.26% for XAIR